Dermata Completes Enrollment In Phase 3 STAR-1 Trial For DMT310 Acne Treatment, Topline Results Expected March 2025, Following Successful Phase 2b Primary Endpoint Achievement
Dermata Completes Enrollment In Phase 3 STAR-1 Trial For DMT310 Acne Treatment, Topline Results Expected March 2025, Following Successful Phase 2b Primary Endpoint Achievement
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.